Promising Role of Postoperative Stereotactic Radiation Therapy for Patients with Prostate Cancer.

Abstract

Radiation therapy is the standard therapeutic option in patients with prostate cancer (PCa) after radical prostatectomy (RPE), the indications for which are a high risk of postoperative progression (adjuvant radiation therapy) or registration of biochemical (clinical) recurrence of the disease (salvage radiation therapy). In recent years, studies have been conducted to assess the efficacy and safety of the use of hypofractionated radiation regimens in this category of patients, which significantly reduce the duration of treatment. Starting from 2016, the regimen of extreme hypofractionation or stereotactic radiation therapy (STRT) to the prostate bed (PB) began to be used in world practice, which makes it possible to deliver the prescribed dose in five-seven fractions. Currently, the N.N. Petrov National Medical Research Center of Oncology has matured long-term (more than five years) experience in performing STRT to the PB. The purpose of this work — to inform oncourologists, radiation oncologists and specialists in related areas with various aspects of a new perspective approach to postoperative radiation to the PB.